pharma · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · RLMD
RELMADA THERAPEUTICS
RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Coral Gables, USA
- Founded
- 2004
- Employees
- 33
- Programs
- 6
- Drugs
- 5
- Patents
- 7
RELMADA THERAPEUTICS projects
6 ClinicalTrials.gov programs sponsored by RELMADA THERAPEUTICS.
RELMADA THERAPEUTICS has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer
2 trials -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
1 trial -
REL-1017
RELMADA THERAPEUTICS, INC.
Major Depressive Disorder
3 trials -
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
RELMADA THERAPEUTICS, INC.
Non Muscle Invasive Bladder Cancer
1 trial -
REL-1017
RELMADA THERAPEUTICS, INC.
Depressive Disorder, Major
1 trial -
REL-1017
RELMADA THERAPEUTICS, INC.
Neuropathic Pain
2 trials
Frequently asked questions
How many clinical projects does RELMADA THERAPEUTICS have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.